Explore Business Standard
Kiran Mazumdar Shaw
Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4
Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .
Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .
Biocon Chairperson Kiran Mazumdar-Shaw on Friday said the convergence of biological intelligence and artificial intelligence (AI) can drive a paradigm shift in medicine, enabling breakthroughs in predictive healthcare, regenerative science and lifespan management. "Biology on its own was limited in generating deeper insights, but AI tools are opening immeasurable opportunities to understand living systems," Mazumdar-Shaw said while speaking at the AI Impact Summit here. She noted that biological systems function like distributed data centres, processing information with minimal energy compared to gigawatt-powered AI systems. "Biology has a lot to teach AI in terms of how to do it with less energy, how to do it rapidly, and how to multiplex multimodal data very quickly," she said. Mazumdar-Shaw described reprogramming cells - such as converting malignant cancer cells into non-malignant ones - as the 'holy grail' of medicine. She said AI could accelerate regenerative science and hel
Biocon Chairperson Kiran Mazumdar-Shaw on Friday said the convergence of biological intelligence and artificial intelligence (AI) can drive a paradigm shift in medicine, enabling breakthroughs in predictive healthcare, regenerative science and lifespan management. "Biology on its own was limited in generating deeper insights, but AI tools are opening immeasurable opportunities to understand living systems," Mazumdar-Shaw said while speaking at the AI Impact Summit here. She noted that biological systems function like distributed data centres, processing information with minimal energy compared to gigawatt-powered AI systems. "Biology has a lot to teach AI in terms of how to do it with less energy, how to do it rapidly, and how to multiplex multimodal data very quickly," she said. Mazumdar-Shaw described reprogramming cells - such as converting malignant cancer cells into non-malignant ones - as the 'holy grail' of medicine. She said AI could accelerate regenerative science and hel
Biocon chief Kiran Mazumdar-Shaw on Tuesday met Chief Minister Siddaramaiah and his deputy D K Shivakumar and greeted them on the occasion of Diwali, official sources said. Shaw has been critical of Bengaluru's infrastructure woes by highlighting them through her social media posts, and has been repeatedly urging the state government to intervene. "Biocon chief Kiran Muzumdar-Shaw visited Cauvery (CM's official residence) and wished Chief Minister Siddaramaiah on Diwali. Legislative Council Chairman Basavaraj Horatti was present on the occasion," the CM's office said in a statement. Shah met Shivakumar at his Sadashivanagar residence in Bengaluru, the Deputy CM's office said. The state government has come under criticism over the poor state of roads and traffic issues in the city for some time now, with industry veterans like former Infosys CFO Mohandas Pai and Shaw repeatedly openly urging the state government to immediately intervene. Faced with mounting criticism from industry